Skip to main content
Clinical Trials/NCT02270723
NCT02270723UnknownPhase 4

Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery

Kirsten Cleemann Rasmussen1 site in 1 country40 target enrollmentStarted: August 2014Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
Measurement of coagulation during surgery and in the recovery room

Study Overview

Brief Summary

In a randomized clinical trial, the purpose is to investigate if perioperative coagulation and hemorrhage is influenced by colloid or crystalloid.

Detailed Description

5% Human Albumin is used for fluid therapy during surgery. This study evaluate whether affected coagulation competence induced by Human Albumin leads to a significant perioperative blood loss when compared to administration of lactated Ringer´s solution.

Data are gathered by the investigators, analysed by the sponsor, and remain confidential throughout the process. The investigators shall be involved in all stages of the study development and vouch for the completeness and accuracy of the data. No third part shall influence the protocol, trial conduct, data analysis, or reporting.

The investigators will include 40 patients undergoing cystectomy. Heart rate, mean arterial pressure, cardiac output are measured after induction of anaesthesia and insertion of the arterial catheter (T0), after establishing normovolaemia but before surgery (T1), after resection of the urinary bladder (T2), at the end of the surgery (T3), and two hours thereafter in the recovery room (T4).

Arterial blood is drawn for whole blood viscoelastic haemostatic assays to record clot initiation (R-Time), formation (Maximal Amplitude, MA), alpha angle(α) and lysis (Ly30) depicting haemostatic competence (thrombelastography). The investigators analyze blood for haemoglobin, creatinine, platelets, and fibrinogen. Furthermore, blood is drawn from the central venous catheter for lactate and blood gas variables (ABL 825, Radiometer, Copenhagen, Denmark). To avoid excessive administration of Human Albumin, patients receive lactated Ringer´s solution if considered needed after the infusion 25 mL/kg of the allocated fluid (non-study fluid).

The fluid balance inclusive the blood loss was calculated after cystectomy, at the end of surgery, and two hours thereafter. The investigators register complications postoperatively inclusive hospital stay until discharge.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient more than 18 years old
  • Indication for elective post-renal operation including cystectomy
  • Patient without anticoagulative, acetylsalicylic acid or nonsteroidal antiinflammatory drug
  • treatment for the last 5 days

Exclusion Criteria

  • Intracerebral bleeding, manifest cardiac insufficient, renal insufficient demanding dialysis, hepatic or coagulation diseases
  • Pregnant or nursing
  • Allergic to Human Albumin
  • Disturbance in electrolytes
  • Patient under committee
  • Patient joining another trial interfering the actual trial

Arms & Interventions

Human Albumin " Behring"

Active Comparator

Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours

Intervention: 5% Human Albumin " Behring" (Drug)

Lactated Ringer

Placebo Comparator

Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours

Intervention: Lactated Ringer (Drug)

Outcomes

Primary Outcomes

Measurement of coagulation during surgery and in the recovery room

Time Frame: up to 1 day after surgery

Changes in fibrinogen, platelets, hemoglobin, alpha angle and maximum amplitude

Secondary Outcomes

  • Measurement of postoperative surgical complications(From date of operation up to 1 months postoperatvely)
  • Measurement of hemorrhage and use of blood products during anesthesia and in the recovery room(up to 1 day after surgery)

Investigators

Sponsor
Kirsten Cleemann Rasmussen
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Kirsten Cleemann Rasmussen

MD, Specialist in Surgery

Rigshospitalet, Denmark

Study Sites (1)

Loading locations...

Similar Trials